A dual GIP/GLP-1 receptor agonist shown to deliver up to 20% body weight reduction in clinical trials. Individual results may vary.
From $199/month
30 Day Money Back Guarantee
*Prescription required. Not all patients qualify. This is a compounded medication prepared by a licensed 503A pharmacy and is not an FDA-approved product.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. Unlike single-action GLP-1 medications, tirzepatide activates two key hormone pathways simultaneously for enhanced weight loss results. Individual results may vary.
Tirzepatide activates both GLP-1 and GIP receptors, working on two complementary pathways to regulate appetite, blood sugar, and metabolism more effectively than single-receptor medications.
The dual mechanism provides stronger appetite suppression, helping you feel satisfied with smaller portions and significantly reducing food cravings and "food noise."
GIP receptor activation improves insulin sensitivity and supports fat metabolism, helping your body more efficiently process and burn stored fat for energy.
By regulating both blood sugar and insulin levels through dual pathways, tirzepatide helps maintain steady energy throughout the day without crashes or fatigue.
Tirzepatide treatment follows a gradual dose escalation to optimize your results while keeping side effects manageable.
Starting at a low dose, your body adjusts to the medication. Many patients notice reduced appetite and fewer cravings within the first week. Mild GI side effects may occur but typically resolve quickly.
Your dose increases gradually. Consistent weight loss begins, which may produce faster weight loss than single-action GLP-1 medications based on clinical trial data. Some patients may lose approximately 5-8 lbs per month during this phase, though individual results vary.
At your optimal dose, weight loss accelerates significantly. The SURMOUNT-1 trial showed patients achieving 16-22.5% body weight reduction. Individual results may vary. Noticeable changes in body composition and energy.
Continued progress toward your goal weight. The SURMOUNT-5 trial demonstrated an average of 20.2% body weight reduction over 72 weeks. Individual results may vary. Continued progress toward weight management goals.
Side effects are generally similar to other GLP-1 medications and most commonly occur during the dose escalation period.
Common side effects include:
Less common but serious side effects (contact your provider immediately):
Important Safety Information: Tirzepatide may cause thyroid C-cell tumors. It is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss your full medical history with your provider.
Every DirectGLP tirzepatide plan includes comprehensive care and support.
Tirzepatide is a dual GIP/GLP-1 receptor agonist - a first-in-class medication that activates two hormone pathways simultaneously. It has been shown to produce greater weight loss than single-action GLP-1 medications in head-to-head clinical trials. This is a compounded medication prepared by a licensed 503A pharmacy and is not an FDA-approved product.
While semaglutide activates only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP receptors. In the SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss compared to 13.7% with semaglutide over 72 weeks. Individual results may vary. Your provider will help determine which medication is best for you.
Tirzepatide is a once-weekly subcutaneous injection, typically administered in the abdomen, thigh, or upper arm. The injection uses a small needle and most patients find it quick and nearly painless. All injection supplies are included with your plan.
In the SURMOUNT-5 trial published in the New England Journal of Medicine, patients using tirzepatide lost an average of 20.2% of their body weight over 72 weeks, with 48.4% of participants achieving at least 20% weight loss. Individual results vary based on starting weight, diet, exercise, and adherence to the treatment plan.
Pricing depends on the specific formulation, dosing schedule, and supply factors. We work directly with licensed pharmacies to provide the most competitive pricing possible for all our GLP-1 medications. Multi-month plans offer significant savings over the monthly rate.
Yes, your provider can help you switch between medications if needed. Some patients may respond better to one medication over another, and your treatment can be adjusted based on your progress and how you feel.
Yes. All GLP-1 medications require a valid prescription from a licensed healthcare provider. During your online assessment, a provider will review your health history and determine if tirzepatide is medically appropriate for you. Medication is only dispensed after provider approval.
Take our quick assessment to see if tirzepatide injections are right for you.
Contact Us
Copyright © DirectGLP. All Rights Reserved